CCR2 and type 2 diabetes mellitus: However a CCR2 antagonist (CCX140-B) shows therapeutic effect on type II diabetes in a phase II trial without affecting the blood monocyte count [36], suggesting that targeting CCR2 could remain as an important therapeutic strategy for metastatic cancer.